Should I buy or sell Abcam stock right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Abcam in the last twelve months. There are currently 5 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" ABCM shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ABCM, but not buy additional shares or sell existing shares. View ABCM analyst ratings or view top-rated stocks .

What is Abcam's stock price target for 2024?

6 Wall Street analysts have issued 1-year target prices for Abcam's stock. Their ABCM share price targets range from $23.00 to $23.00. On average, they anticipate the company's stock price to reach $23.00 in the next twelve months. This suggests that the stock has a possible downside of 4.1%. View analysts price targets for ABCM or view top-rated stocks among Wall Street analysts .

How have ABCM shares performed in 2023?

Abcam's stock was trading at $15.56 at the start of the year. Since then, ABCM stock has increased by 54.2% and is now trading at $23.99. View the best growth stocks for 2023 here .

Are investors shorting Abcam?

Abcam saw a increase in short interest in November. As of November 15th, there was short interest totaling 5,580,000 shares, an increase of 36.8% from the October 31st total of 4,080,000 shares. Based on an average daily volume of 7,370,000 shares, the short-interest ratio is presently 0.8 days. View Abcam's Short Interest .

What ETFs hold Abcam's stock?

ETFs with the largest weight of Abcam (NASDAQ:ABCM) stock in their portfolio include BlackRock Future Health ETF (BMED) , Invesco Nasdaq Biotechnology ETF (IBBQ) and iShares Biotechnology ETF (IBB) . ProShares Ultra Nasdaq Biotechnology (BIB) .

(ABCM) raised $149 million in an initial public offering (IPO) on Thursday, October 22nd 2020. The company issued 9,000,000 shares at $16.52 per share. Morgan Stanley, BofA Securities, SVB Leerink, Lazard and William Blair served as the underwriters for the IPO.

Who are Abcam's major shareholders?

Abcam's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Baillie Gifford & Co. (3.19%), Soros Fund Management LLC (2.70%), JPMorgan Chase & Co. (2.64%), Brown Advisory Inc. (2.25%), KRYGER CAPITAL Ltd (2.04%) and Wellington Management Group LLP (2.02%).

How do I buy shares of Abcam?

Shares of ABCM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Abcam (ABCM) Stock Price, News & Analysis

$23.99

+0.01 (+0.04%)

(As of 12/5/2023)

Compare

Today's Range: $23.98
▼
$24.00
50-Day Range: $22.61
▼
$23.99
52-Week Range: $12.48
▼
$25.32

Volume: 7.43 million shs
Average Volume: 3.08 million shs
Market Capitalization: $5.50 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $23.00

Abcam MarketRank™ Stock Analysis

Analyst Rating: Hold
2.17 Rating Score
Upside/Downside: 4.1% Downside
$23.00 Price Target
Short Interest: Healthy
2.43% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.55
Based on 5 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: 29.55%
From $0.44 to $0.57 Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.52 out of 5 stars

Medical Sector

856th out of 942 stocks

Biotechnology Industry

31st out of 41 stocks

1.1

Analyst's Opinion

Consensus Rating
Abcam has received a consensus rating of Hold. The company's average rating score is 2.17, and is based on 1 buy rating, 5 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $23.00, Abcam has a forecasted downside of 4.1% from its current price of $23.99.
Amount of Analyst Coverage
Abcam has only been the subject of 1 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
2.43% of the outstanding shares of Abcam have been sold short.
Short Interest Ratio / Days to Cover
Abcam has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Abcam has recently increased by 36.76%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Abcam does not currently pay a dividend.
Dividend Growth
Abcam does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ABCM.

2.0

News and Social Media Coverage

News Sentiment
Abcam has a news sentiment score of 0.55. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 5 news articles for Abcam this week, compared to 2 articles on an average week.
MarketBeat Follows
Only 1 people have added Abcam to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Abcam insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 6.73% of the stock of Abcam is held by insiders.
Percentage Held by Institutions
90.45% of the stock of Abcam is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.9

Earnings and Valuation

Earnings Growth
Earnings for Abcam are expected to grow by 29.55% in the coming year, from $0.44 to $0.57 per share.
Price to Earnings Growth Ratio
Abcam has a PEG Ratio of 2.19. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
Abcam has a P/B Ratio of 6.12. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Abcam Stock (NASDAQ:ABCM)

Abcam plc, a life science company, focuses on identifying, developing, and distributing reagents and tools for scientific research, diagnostics, and drug discovery. The company's principal products include primary and secondary antibodies; conjugated antibodies and conjugation kits; singleplex immunoassays; proteins and peptides that include cytokines; edited cell lines and lysates; and various other products, including cellular activity kits, biochemicals, and cell signaling pathway tools. It serves scientists and researchers in academic institutions and research institutes, as well as in pharmaceutical, biotechnology, and diagnostics companies. The company has operations in the Americas, Europe, the Middle East, Africa, China, Japan, and rest of the Asia Pacific. It sells its products online. The company was incorporated in 1998 and is headquartered in Cambridge, the United Kingdom.

ABCM Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ABCM Stock News Headlines

December 8, 2023 | finance.yahoo.com

Abcam plc (ABCM) Interactive Stock Chart - Yahoo Finance

December 6, 2023 | americanbankingnews.com

Abcam plc (NASDAQ:ABCM) Receives Consensus Recommendation of "Hold" from Analysts

December 11, 2023 | Wealthpress (Ad)

Trading Experts Call It “The Perfect Tesla Trade”

Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.

December 5, 2023 | americanbankingnews.com

Reviewing aTyr Pharma (NASDAQ:LIFE) & Abcam (NASDAQ:ABCM)

November 17, 2023 | markets.businessinsider.com

Abcam-Danaher Deal Receives All Identified Clearances - Quick Facts

November 15, 2023 | finance.yahoo.com

Here’s Headwaters Capital’s Perspective on Abcam plc (ABCM) Acquisition

November 6, 2023 | tmcnet.com

Shareholders of Abcam Approve Proposed Acquisition by Danaher

November 1, 2023 | benzinga.com

Statement from Dr. Jonathan Milner on the suspension of the "Vote AGAINST" campaign

December 11, 2023 | Wealthpress (Ad)

Trading Experts Call It “The Perfect Tesla Trade”

November 1, 2023 | finanznachrichten.de

Abcam plc: Leading Proxy Advisor, ISS, Recommends Shareholders Vote "FOR" Danaher Corporation's Proposed Acquisition of Abcam

October 23, 2023 | stockhouse.com

Leading Independent Proxy Advisor Glass Lewis Joins ISS in Recommending Shareholders Vote "FOR" Danaher Corporation's Proposed Acquisition of Abcam

October 19, 2023 | finance.yahoo.com

She Blinded Me with Science – ISS Makes Schoolboy Error on Abcam Deal

October 17, 2023 | finance.yahoo.com

Leading Proxy Advisor, ISS, Recommends Shareholders Vote "FOR" Danaher Corporation’s Proposed Acquisition of Abcam

October 16, 2023 | markets.businessinsider.com

Jonathan Milner Issues Statement Responding to ISS Report

October 16, 2023 | msn.com

Abcam holders should vote for sale to Danaher, proxy adviser ISS says (update)

October 16, 2023 | finance.yahoo.com

Jonathan Milner releases presentation to Abcam plc shareholders, outlining reasons to reject Danaher's bid and strategic vision for the Company

October 9, 2023 | markets.businessinsider.com

Abcam (ABCM) Gets a Hold from RBC Capital

October 5, 2023 | msn.com

GMED or ABCM: Which Is the Better Value Stock Right Now?

October 5, 2023 | finanznachrichten.de

Abcam plc: Abcam Files and Mails Scheme Circular Seeking Approval of Acquisition of Abcam by Danaher for $24.00 per Share

September 21, 2023 | finance.yahoo.com

Headwaters Capital Calls Out Fishy Bid for Abcam from Danaher in Letter to Stakeholders – Exclusive

September 15, 2023 | msn.com

Abcam holder, founder Jonathan Milner opposes Danaher acquisition (update)

September 14, 2023 | benzinga.com

Abcam plc Statement on Dr. Jonathan Milner's Announcement

September 14, 2023 | msn.com

Abcam holder, founder Jonathan Milner opposes Danaher acquisition

August 31, 2023 | finance.yahoo.com

Abcam plc Interim Results for the Six-Month Period Ended 30 June 2023

August 30, 2023 | msn.com

Abcam cut to market perform at Leerink, sees no antitrust risk

August 29, 2023 | msn.com

Abcam deal price may have been hurt by antitrust concerns - report (update)

August 29, 2023 | benzinga.com

ABCAM INVESTOR ALERT by the Former Attorney...

See More Headlines

Receive ABCM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Abcam and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today: 12/11/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:ABCM
CUSIP: N/A
CIK: 1492074
Web: www.abcam.com
Phone: 44-0-12-2369-6000
Fax: N/A
Employees: 1,760
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $23.00
High Stock Price Target: $23.00
Low Stock Price Target: $23.00
Potential Upside/Downside: -4.1%
Consensus Rating: Hold
Rating Score (0-4): 2.17
Research Coverage: 6 Analysts

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: 54.52
P/E Growth: 2.19
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 1.35
Quick Ratio: 1.00

Sales & Book Value

Annual Sales: $379.70 million
Price / Sales: 14.49
Cash Flow: $0.60 per share
Price / Cash Flow: 40.17
Book Value: $3.92 per share
Price / Book: 6.12

Miscellaneous

Outstanding Shares: 229,272,000
Free Float: 213,842,000
Market Cap: $5.50 billion
Optionable: Not Optionable
Beta: 0.86

7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

Mr. Alan Thomas Hirzel BS (Age 55)
M.B.A., M.S., CEO & Executive Director
Comp: $1.18M
Mr. Michael Shaun Baldock B.A. (Age 59)
CFO & Director
Comp: $876.48k
Marc Leigh Russell Perkins
General Counsel & Company Secretary
Emma Sceats
Senior Vice President of Sales & Marketing
Mr. Nick Skinner
Senior Vice President of Human Resources
Ms. Alejandra Solache Ph.D.
Senior Vice President of Research & Development
Mr. John Baker
Senior Vice President of Supply Chain & Manufacturing
Juan Carlos Sacristan
Senior Vice President of Data & Digital

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

ABCM Stock Analysis - Frequently Asked Questions

Should I buy or sell Abcam stock right now?: 6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Abcam in the last twelve months. There are currently 5 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" ABCM shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ABCM, but not buy additional shares or sell existing shares.
View ABCM analyst ratings or view top-rated stocks.
What is Abcam's stock price target for 2024?: 6 Wall Street analysts have issued 1-year target prices for Abcam's stock. Their ABCM share price targets range from $23.00 to $23.00. On average, they anticipate the company's stock price to reach $23.00 in the next twelve months. This suggests that the stock has a possible downside of 4.1%.
View analysts price targets for ABCM or view top-rated stocks among Wall Street analysts.
How have ABCM shares performed in 2023?: Abcam's stock was trading at $15.56 at the start of the year. Since then, ABCM stock has increased by 54.2% and is now trading at $23.99.
View the best growth stocks for 2023 here.
Are investors shorting Abcam?: Abcam saw a increase in short interest in November. As of November 15th, there was short interest totaling 5,580,000 shares, an increase of 36.8% from the October 31st total of 4,080,000 shares. Based on an average daily volume of 7,370,000 shares, the short-interest ratio is presently 0.8 days.
View Abcam's Short Interest.

What ETFs hold Abcam's stock?: ETFs with the largest weight of Abcam (NASDAQ:ABCM) stock in their portfolio include BlackRock Future Health ETF (BMED), Invesco Nasdaq Biotechnology ETF (IBBQ) and iShares Biotechnology ETF (IBB).ProShares Ultra Nasdaq Biotechnology (BIB).
When did Abcam IPO?: (ABCM) raised $149 million in an initial public offering (IPO) on Thursday, October 22nd 2020. The company issued 9,000,000 shares at $16.52 per share. Morgan Stanley, BofA Securities, SVB Leerink, Lazard and William Blair served as the underwriters for the IPO.
Who are Abcam's major shareholders?: Abcam's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Baillie Gifford & Co. (3.19%), Soros Fund Management LLC (2.70%), JPMorgan Chase & Co. (2.64%), Brown Advisory Inc. (2.25%), KRYGER CAPITAL Ltd (2.04%) and Wellington Management Group LLP (2.02%).
How do I buy shares of Abcam?: Shares of ABCM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:ABCM) was last updated on 12/11/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial